New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

SAN JOSE, Antique (PIA) — The municipality of Tobias Fornier recently activated its Barangay Information Officers (BIO) ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay under exposure to ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

Researchers have demonstrated that E. coli can perform a biocompatible Lossen rearrangement, enabling phosphate-catalysed ...

Sierra Leone's President Julius Maada Bio has been elected as the new Chairman of the ECOWAS Authority of Heads of State and ...

Fossils described in a new study speak to a previously unknown large-bodied lizard diversity that existed alongside dinosaurs ...